Serkan Akın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Serkan Akın has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Barista
Department of Medical Oncology, Hacettepe University, Ankara 06230, Türkiye
5 shared publications - Omer Dizdar
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
3 shared publications - Aysegul Uner
Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
2 shared publications - Deniz Can Guven
Department of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey
2 shared publications - Ece Özoğul
Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
2 shared publications - Fatma Alev Türker
Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Sihhiye, 06100 Ankara, Turkey
2 shared publications
Latest Publications
- 12 September 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (6) , 1264-1266
MALT lymphoma with synchronous lacrimal gland and gastric involvement on 18F-FDG PET/CT: A rare presentation
- 12 September 2026
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (6) , 1264-1266
MALT lymphoma with synchronous lacrimal gland and gastric involvement on 18F-FDG PET/CT: A rare presentation
- 11 September 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 54
Large B-cell lymphoma with IRF4 rearrangement: clinicopathologic heterogeneity across the age spectrum
- 11 September 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 54
Large B-cell lymphoma with IRF4 rearrangement: clinicopathologic heterogeneity across the age spectrum
- Open Access
Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey
Background and Objectives: Kaposi sarcoma (KS) is a rare angioproliferative malignancy driven by human herpesvirus-8 infection. Comparative real-world data on classic and AIDS-related KS from Mediterranean-endemic countries remain limited. Materials and Methods: We retrospectively analyzed 102 patients with histopathologically confirmed KS treated across five tertiary oncology centers in Turkey between January 2010 and December 2023. Demographic characteristics, clinical features, treatment patterns, and survival outcomes were compared between classic and AIDS-related KS subtypes. Results: Ninety-two patients (90.2%) had classic KS and ten (9.8%) had AIDS-related KS. The median age at diagnosis was significantly higher in the classic KS group (69 vs. 38.5 years; p < 0.001). Male sex predominated in both groups (classic KS: 76.1%; AIDS-related KS: 100%; p = 0.113). AIDS-related KS presented with more advanced disease at diagnosis, with 70% classified as poor-risk by ACTG-TIS criteria versus 9.8% Stage IV by Brambilla criteria in classic KS, and more frequent extracutaneous involvement (70% vs. 8.7%; p < 0.001). Paclitaxel was the most commonly used first-line agent in classic KS (42.9%), while pegylated liposomal doxorubicin predominated in AIDS-related KS (87.5%). Overall response rates were high and comparable between groups (90.7% vs. 88.9%). Median overall survival was significantly longer in classic KS (66.9 vs. 22.67 months; p = 0.012). Disease stage and lesion morphology were not significantly associated with survival in either group. Conclusions: Classic and AIDS-related KS differ substantially in clinical presentation and survival outcomes, yet demonstrate comparable chemosensitivity. Our findings in the AIDS-related Kaposi sarcoma group are preliminary and hypothesis-generating due to the small sample size, requiring confirmation in larger prospective cohorts.
Open AccessDemographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey
Background and Objectives: Kaposi sarcoma (KS) is a rare angioproliferative malignancy driven by human herpesvirus-8 infection. Comparative real-world data on classic and AIDS-related KS from Mediterranean-endemic countries remain limited. Materials and Methods: We retrospectively analyzed 102 patients with histopathologically confirmed KS treated across five tertiary oncology centers in Turkey between January 2010 and December 2023. Demographic characteristics, clinical features, treatment patterns, and survival outcomes were compared between classic and AIDS-related KS subtypes. Results: Ninety-two patients (90.2%) had classic KS and ten (9.8%) had AIDS-related KS. The median age at diagnosis was significantly higher in the classic KS group (69 vs. 38.5 years; p < 0.001). Male sex predominated in both groups (classic KS: 76.1%; AIDS-related KS: 100%; p = 0.113). AIDS-related KS presented with more advanced disease at diagnosis, with 70% classified as poor-risk by ACTG-TIS criteria versus 9.8% Stage IV by Brambilla criteria in classic KS, and more frequent extracutaneous involvement (70% vs. 8.7%; p < 0.001). Paclitaxel was the most commonly used first-line agent in classic KS (42.9%), while pegylated liposomal doxorubicin predominated in AIDS-related KS (87.5%). Overall response rates were high and comparable between groups (90.7% vs. 88.9%). Median overall survival was significantly longer in classic KS (66.9 vs. 22.67 months; p = 0.012). Disease stage and lesion morphology were not significantly associated with survival in either group. Conclusions: Classic and AIDS-related KS differ substantially in clinical presentation and survival outcomes, yet demonstrate comparable chemosensitivity. Our findings in the AIDS-related Kaposi sarcoma group are preliminary and hypothesis-generating due to the small sample size, requiring confirmation in larger prospective cohorts.
- Open Access
Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort—A Turkish Oncology Group (TOG) Study
Background and Objectives: Comprehensive real-world data on dose-adjusted EPOCH-R (DA-EPOCH-R) incorporating molecular prognostic stratification remain limited. We evaluated the long-term efficacy, safety, and prognostic determinants of DA-EPOCH-R in a multicenter Turkish cohort. Materials and Methods: This retrospective study included 140 patients with aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], n = 81; primary mediastinal B-cell lymphoma [PMBL], n = 39; other, n = 20) treated with DA-EPOCH-R at five academic centers (2015–2020). Molecular profiling included immunohistochemistry (MYC, BCL-2, BCL-6) and fluorescence in situ hybridization (FISH). Survival was estimated by Kaplan–Meier analysis with Cox regression for prognostic factors. Results: At a median follow-up of 50.1 months, 5-year overall survival (OS) and event-free survival (EFS) rates were 71.3% and 66.3%, respectively (complete response rate: 68.6%). Molecular subtypes included double-expressor (DEL; n = 39), triple-expressor (TEL; n = 21), double-hit (DHL; n = 17), and triple-hit lymphoma (THL; n = 11). Five-year OS by IPI risk group ranged from 88.6% (low) to 49.4% (high) (p = 0.005). DEL status did not confer inferior OS (p = 0.738), whereas DHL and THL had markedly poor outcomes (p < 0.001). In multivariate analysis, IPI ≥ 3 (HR 2.54; p = 0.007) and MYC FISH rearrangement (HR 3.62; p < 0.001) independently predicted inferior OS. Grade 3–4 neutropenia occurred in 57.1%, with no grade 3–4 cardiotoxicity. Conclusions: DA-EPOCH-R provides favorable long-term outcomes in aggressive B-cell lymphomas. DEL status did not confer a survival disadvantage, an association that is hypothesis-generating and requires confirmation, as the present design cannot establish a causal mechanism. FISH-defined DHL/THL remain associated with dismal outcomes, warranting novel therapeutic strategies.
Open AccessDose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort—A Turkish Oncology Group (TOG) Study
Background and Objectives: Comprehensive real-world data on dose-adjusted EPOCH-R (DA-EPOCH-R) incorporating molecular prognostic stratification remain limited. We evaluated the long-term efficacy, safety, and prognostic determinants of DA-EPOCH-R in a multicenter Turkish cohort. Materials and Methods: This retrospective study included 140 patients with aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], n = 81; primary mediastinal B-cell lymphoma [PMBL], n = 39; other, n = 20) treated with DA-EPOCH-R at five academic centers (2015–2020). Molecular profiling included immunohistochemistry (MYC, BCL-2, BCL-6) and fluorescence in situ hybridization (FISH). Survival was estimated by Kaplan–Meier analysis with Cox regression for prognostic factors. Results: At a median follow-up of 50.1 months, 5-year overall survival (OS) and event-free survival (EFS) rates were 71.3% and 66.3%, respectively (complete response rate: 68.6%). Molecular subtypes included double-expressor (DEL; n = 39), triple-expressor (TEL; n = 21), double-hit (DHL; n = 17), and triple-hit lymphoma (THL; n = 11). Five-year OS by IPI risk group ranged from 88.6% (low) to 49.4% (high) (p = 0.005). DEL status did not confer inferior OS (p = 0.738), whereas DHL and THL had markedly poor outcomes (p < 0.001). In multivariate analysis, IPI ≥ 3 (HR 2.54; p = 0.007) and MYC FISH rearrangement (HR 3.62; p < 0.001) independently predicted inferior OS. Grade 3–4 neutropenia occurred in 57.1%, with no grade 3–4 cardiotoxicity. Conclusions: DA-EPOCH-R provides favorable long-term outcomes in aggressive B-cell lymphomas. DEL status did not confer a survival disadvantage, an association that is hypothesis-generating and requires confirmation, as the present design cannot establish a causal mechanism. FISH-defined DHL/THL remain associated with dismal outcomes, warranting novel therapeutic strategies.
- Open Access
- 4 June 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 611
Clinical and geriatric factors associated with fracture risk in older adults with bone metastases: A prospective observational study
Purpose: Bone metastases frequently lead to fractures, causing substantial morbidity, impaired quality of life, and poor prognosis in older adults with cancer. This study aimed to evaluate fracture risk by integrating geriatric parameters with clinical and oncological factors in older patients with bone metastases. Methods: This prospective observational study included 55 patients aged ≥ 65 years with newly diagnosed bone metastases who initiated monthly parenteral antiresorptive therapy. Baseline evaluation included standard oncological variables and validated geriatric tools (ADL, MUST, mFI-5, and ACB). Fracture occurrence was monitored over a six-month follow-up period. Univariate Cox regression analyses were performed to identify fracture-associated factors, followed by a theoretically driven multivariable Cox regression model. Correlation analyses were used to assess associations among significant variables. Results: Fractures occurred in 21 patients (38.2%). Univariate analyses showed that poorer performance status (ECOG ≥ 1; HR = 19.92), moderate functional impairment (ADL 3–5; HR = 8.39), high frailty (mFI-5 ≥ 2; HR = 9.83), osteolytic lesions (HR = 4.87), high anticholinergic burden (ACB ≥ 3; HR = 4.56), malnutrition risk (MUST ≥ 2; HR = 4.30), post-study falls (HR = 4.22), and lung metastases (HR = 2.97) were associated with increased fracture risk. Multivariable analysis identified ECOG score of 1 (aHR = 20.62) and high ACB score (aHR = 5.70) as independent predictors. Reduced functional independence and poorer performance status showed the strongest correlations with fracture occurrence. Conclusion: Fracture risk in older adults with bone metastases is driven predominantly by functional impairment, frailty, and medication-related vulnerability rather than tumor-related factors alone. Integrating geriatric assessment into routine oncology practice may improve fracture risk stratification and supportive care outcomes.
- 4 June 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 611
Open AccessClinical and geriatric factors associated with fracture risk in older adults with bone metastases: A prospective observational study
Purpose: Bone metastases frequently lead to fractures, causing substantial morbidity, impaired quality of life, and poor prognosis in older adults with cancer. This study aimed to evaluate fracture risk by integrating geriatric parameters with clinical and oncological factors in older patients with bone metastases. Methods: This prospective observational study included 55 patients aged ≥ 65 years with newly diagnosed bone metastases who initiated monthly parenteral antiresorptive therapy. Baseline evaluation included standard oncological variables and validated geriatric tools (ADL, MUST, mFI-5, and ACB). Fracture occurrence was monitored over a six-month follow-up period. Univariate Cox regression analyses were performed to identify fracture-associated factors, followed by a theoretically driven multivariable Cox regression model. Correlation analyses were used to assess associations among significant variables. Results: Fractures occurred in 21 patients (38.2%). Univariate analyses showed that poorer performance status (ECOG ≥ 1; HR = 19.92), moderate functional impairment (ADL 3–5; HR = 8.39), high frailty (mFI-5 ≥ 2; HR = 9.83), osteolytic lesions (HR = 4.87), high anticholinergic burden (ACB ≥ 3; HR = 4.56), malnutrition risk (MUST ≥ 2; HR = 4.30), post-study falls (HR = 4.22), and lung metastases (HR = 2.97) were associated with increased fracture risk. Multivariable analysis identified ECOG score of 1 (aHR = 20.62) and high ACB score (aHR = 5.70) as independent predictors. Reduced functional independence and poorer performance status showed the strongest correlations with fracture occurrence. Conclusion: Fracture risk in older adults with bone metastases is driven predominantly by functional impairment, frailty, and medication-related vulnerability rather than tumor-related factors alone. Integrating geriatric assessment into routine oncology practice may improve fracture risk stratification and supportive care outcomes.
- Open Access
- 16 September 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (5) , 934-938
A retrospective multicenter study on solitary fibrous tumors: investigation of clinical features and management approaches
Aims: Solitary fibrous tumors are exceedingly rare neoplasms, for which surgical resection remains the cornerstone of treatment; however, long-term surveillance is imperative due to the significant risk of recurrence. We aimed to evaluate tumor characteristics and treatment responses in this multicenter study. Methods: Sixty-eight adult patients with histologically confirmed solitary fibrous tumor (SFT) diagnosed between 2010 and 2024 from seven cancer centers in Turkiye were included. Clinical and pathological features along with treatment outcomes were assessed. Results: The majority of patients (65/68 pts, 95%) presented with localized disease and underwent primary resection, while 3 patients had metastatic disease at the time of diagnosis. Further analyses were performed only in patients with localized disease. Median follow-up time was 41.7 months. All patients underwent primary surgery; R0 resection was achieved in most patients (66.2%). Five -year DFS and OS were 67% and 87%, respectively. DFS of extrameningeal SFTs was further evaluated according to clinicopathological variables. Low Ki-67 Labeling Index, low mitotic rate, and younger age were found to be associated with longer DFS. Response rates to first-line systemic therapy after recurrence was 27% with chemotherapy and while no objective responses were achieved with pazopanib. Two patients experienced disease control for up to 11 months with pazopanib. This study is limited by the relatively small sample size and the heterogeneity arising from the inclusion of both meningeal and extrameningeal tumors located at different anatomical sites. Conclusion: Localized SFTs usually have favorable prognosis. Patients with extrameningeal SFTs with younger age, low Ki-67 Index and low mitotic rate have longer survival. Once relapsed, repeat surgical resection should be pursued when possible. Response rates to systemic treatment is generally low.
- 16 September 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (5) , 934-938
Open AccessA retrospective multicenter study on solitary fibrous tumors: investigation of clinical features and management approaches
Aims: Solitary fibrous tumors are exceedingly rare neoplasms, for which surgical resection remains the cornerstone of treatment; however, long-term surveillance is imperative due to the significant risk of recurrence. We aimed to evaluate tumor characteristics and treatment responses in this multicenter study. Methods: Sixty-eight adult patients with histologically confirmed solitary fibrous tumor (SFT) diagnosed between 2010 and 2024 from seven cancer centers in Turkiye were included. Clinical and pathological features along with treatment outcomes were assessed. Results: The majority of patients (65/68 pts, 95%) presented with localized disease and underwent primary resection, while 3 patients had metastatic disease at the time of diagnosis. Further analyses were performed only in patients with localized disease. Median follow-up time was 41.7 months. All patients underwent primary surgery; R0 resection was achieved in most patients (66.2%). Five -year DFS and OS were 67% and 87%, respectively. DFS of extrameningeal SFTs was further evaluated according to clinicopathological variables. Low Ki-67 Labeling Index, low mitotic rate, and younger age were found to be associated with longer DFS. Response rates to first-line systemic therapy after recurrence was 27% with chemotherapy and while no objective responses were achieved with pazopanib. Two patients experienced disease control for up to 11 months with pazopanib. This study is limited by the relatively small sample size and the heterogeneity arising from the inclusion of both meningeal and extrameningeal tumors located at different anatomical sites. Conclusion: Localized SFTs usually have favorable prognosis. Patients with extrameningeal SFTs with younger age, low Ki-67 Index and low mitotic rate have longer survival. Once relapsed, repeat surgical resection should be pursued when possible. Response rates to systemic treatment is generally low.
- Open Access
- 8 August 2025
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 3 (3) , 49-56
Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas
Aims: The This study was to determine the clinicopathological findings of patients with primary central nervous system lymphoma (PCNSL) as real-life data, examine their treatment approaches, and define the prognostic factors. Methods: Eighty-four patients who presented with a diagnosis of PCNSL between January 2008 and July 2021 were included in this study. The treatments received by the patients and their survival outcomes were retrospectively analyzed. Results: The median age at diagnosis was 55 (18-80 years). The median progression-free survival (PFS) was 16.8 months (12.4-21.2 months), while the median overall survival (OS) was 18 months (13.7-22.4 months) in all patients. The most commonly used chemotherapy was high-dose methotrexate based regimens, which were preferred in 68 (81%) patients. Objective response rate and disease control rate were 75% and 83.3%, respectively. Consolidation therapy was an independent prognostic factor for PFS (HR:0.32, 95% CI, 0.18-0.55, p<0.001). Patients who received consolidation therapy were observed to have a 67% reduction in mortality compared to those who did not (HR:0.33, 95% CI, 0.19-0.57, p<0.001). Also, high risk in Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model was found to be associated with a 2-fold increase in mortality compared to the good risk group (HR:2.04, 95% CI, 1.02-3.56, p=0.022). Toxicity of any grade was observed in 78 (92.9%) patients. There were 3 (3.6%) patients who died due to treatment toxicity. Conclusion: Consolidation therapy was found to be an independent predictive factor for both OS and PFS in PCNSL. In addition, high risk class according to MSKCC prognostic model was found to be associated with increased mortality.
- 8 August 2025
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 3 (3) , 49-56
Open AccessEvaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas
Aims: The This study was to determine the clinicopathological findings of patients with primary central nervous system lymphoma (PCNSL) as real-life data, examine their treatment approaches, and define the prognostic factors. Methods: Eighty-four patients who presented with a diagnosis of PCNSL between January 2008 and July 2021 were included in this study. The treatments received by the patients and their survival outcomes were retrospectively analyzed. Results: The median age at diagnosis was 55 (18-80 years). The median progression-free survival (PFS) was 16.8 months (12.4-21.2 months), while the median overall survival (OS) was 18 months (13.7-22.4 months) in all patients. The most commonly used chemotherapy was high-dose methotrexate based regimens, which were preferred in 68 (81%) patients. Objective response rate and disease control rate were 75% and 83.3%, respectively. Consolidation therapy was an independent prognostic factor for PFS (HR:0.32, 95% CI, 0.18-0.55, p<0.001). Patients who received consolidation therapy were observed to have a 67% reduction in mortality compared to those who did not (HR:0.33, 95% CI, 0.19-0.57, p<0.001). Also, high risk in Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model was found to be associated with a 2-fold increase in mortality compared to the good risk group (HR:2.04, 95% CI, 1.02-3.56, p=0.022). Toxicity of any grade was observed in 78 (92.9%) patients. There were 3 (3.6%) patients who died due to treatment toxicity. Conclusion: Consolidation therapy was found to be an independent predictive factor for both OS and PFS in PCNSL. In addition, high risk class according to MSKCC prognostic model was found to be associated with increased mortality.
- Open Access
- 10 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4085
Impact of Time-to-Treatment Initiation and First Inter-Cycle Delay in Patients with Hodgkin Lymphoma
Background: Delays in treatments are frequent in real-world lymphoma management. This study evaluates the impact of diagnosis-to-treatment intervals (DTIs) and first inter-cycle delay (IcD) on outcomes in patients with Hodgkin lymphoma (HL) receiving ABVD chemotherapy. Methods: We retrospectively analyzed 137 patients with classical HL treated with ABVD at a single institution between 2015 and 2022. Results: The median age was 34 years (range: 18–73), and 62% were male. The median DTI was 14 days, with 24.1% of patients experiencing a delay of >7 days between the first and second chemotherapy cycles. The most frequent reason for delay was neutropenia, observed in 69% of delayed cases. Neither DTI nor IcD was significantly associated with PFS or OS. Multivariate analysis identified elevated beta-2 microglobulin as an independent predictor of both inferior PFS and OS. Conclusions: This is the first study to evaluate both DTI and first IcD as independent prognostic factors in HL. Modest delays in treatment initiation or early cycle administration did not negatively affect survival. Timely but flexible scheduling of ABVD may be appropriate in HL. Prospective studies are warranted in the era of novel therapeutic agents.
- 10 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4085
Open AccessImpact of Time-to-Treatment Initiation and First Inter-Cycle Delay in Patients with Hodgkin Lymphoma
Background: Delays in treatments are frequent in real-world lymphoma management. This study evaluates the impact of diagnosis-to-treatment intervals (DTIs) and first inter-cycle delay (IcD) on outcomes in patients with Hodgkin lymphoma (HL) receiving ABVD chemotherapy. Methods: We retrospectively analyzed 137 patients with classical HL treated with ABVD at a single institution between 2015 and 2022. Results: The median age was 34 years (range: 18–73), and 62% were male. The median DTI was 14 days, with 24.1% of patients experiencing a delay of >7 days between the first and second chemotherapy cycles. The most frequent reason for delay was neutropenia, observed in 69% of delayed cases. Neither DTI nor IcD was significantly associated with PFS or OS. Multivariate analysis identified elevated beta-2 microglobulin as an independent predictor of both inferior PFS and OS. Conclusions: This is the first study to evaluate both DTI and first IcD as independent prognostic factors in HL. Modest delays in treatment initiation or early cycle administration did not negatively affect survival. Timely but flexible scheduling of ABVD may be appropriate in HL. Prospective studies are warranted in the era of novel therapeutic agents.
- 9 May 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (9) , 1759-1761
Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions
- 9 May 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (9) , 1759-1761
Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions
- Open Access
- 5 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1741
Serum Albumin–Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer
Background: Several studies have suggested that the serum albumin–creatinine ratio (sACR) is a useful marker for the early risk stratification of patients with cardiomyocyte injury. This study aims to evaluate the relationship between sACR and anthracycline-related cardiotoxicity. Methods: This study included patients who had received anthracycline-based chemotherapy between 2014 and 2023 and had undergone baseline and follow-up echocardiography after the treatment. The level of sACR was calculated using serum albumin and creatinine values obtained before the chemotherapy. The definition of cardiotoxicity was based on the criteria of the European Society of Cardiology (ESC) for ejection fraction and the American Society of Echocardiography (ASE) for diastolic dysfunction. The patients were categorized into either the high or low sACR group based on the cut-off value obtained from the receiver operating characteristic (ROC) curve analysis. Results: In total, 525 patients (159 males, 366 females) were included. Multivariate analysis after adjustment for age, body mass index (BMI), cardiovascular disease, hemoglobin, anthracycline dose, and gender showed that sACR (HR = 1.85% 95 CI 1.12 to 3.06 p = 0.016), cardiovascular disease (HR = 1.97% 95 CI 1.08 to 3.61 p = 0.027), BMI (HR = 1.86% 95 CI 1.12 to 3.10 p = 0.017), and age (HR = 1.02% 95 CI 1.001 to 1.04 p = 0.036) were significantly associated with an increased risk of cardiotoxicity. Conclusions: This study is the first to show a significant relationship between sACR and cardiotoxicity related to anthracycline use. Routine laboratory tests that are conducted before anthracycline therapy can aid clinicians in identifying high-risk patients who may require closer follow-up or cardioprotective measures.
- 5 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1741
Open AccessSerum Albumin–Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer
Background: Several studies have suggested that the serum albumin–creatinine ratio (sACR) is a useful marker for the early risk stratification of patients with cardiomyocyte injury. This study aims to evaluate the relationship between sACR and anthracycline-related cardiotoxicity. Methods: This study included patients who had received anthracycline-based chemotherapy between 2014 and 2023 and had undergone baseline and follow-up echocardiography after the treatment. The level of sACR was calculated using serum albumin and creatinine values obtained before the chemotherapy. The definition of cardiotoxicity was based on the criteria of the European Society of Cardiology (ESC) for ejection fraction and the American Society of Echocardiography (ASE) for diastolic dysfunction. The patients were categorized into either the high or low sACR group based on the cut-off value obtained from the receiver operating characteristic (ROC) curve analysis. Results: In total, 525 patients (159 males, 366 females) were included. Multivariate analysis after adjustment for age, body mass index (BMI), cardiovascular disease, hemoglobin, anthracycline dose, and gender showed that sACR (HR = 1.85% 95 CI 1.12 to 3.06 p = 0.016), cardiovascular disease (HR = 1.97% 95 CI 1.08 to 3.61 p = 0.027), BMI (HR = 1.86% 95 CI 1.12 to 3.10 p = 0.017), and age (HR = 1.02% 95 CI 1.001 to 1.04 p = 0.036) were significantly associated with an increased risk of cardiotoxicity. Conclusions: This study is the first to show a significant relationship between sACR and cardiotoxicity related to anthracycline use. Routine laboratory tests that are conducted before anthracycline therapy can aid clinicians in identifying high-risk patients who may require closer follow-up or cardioprotective measures.